EP0358305B1 - Mercapto-phenylalcanoylamino acid amides, their preparation and their use as collagenase inhibitors - Google Patents

Mercapto-phenylalcanoylamino acid amides, their preparation and their use as collagenase inhibitors Download PDF

Info

Publication number
EP0358305B1
EP0358305B1 EP89306228A EP89306228A EP0358305B1 EP 0358305 B1 EP0358305 B1 EP 0358305B1 EP 89306228 A EP89306228 A EP 89306228A EP 89306228 A EP89306228 A EP 89306228A EP 0358305 B1 EP0358305 B1 EP 0358305B1
Authority
EP
European Patent Office
Prior art keywords
formula
hydrogen
methylpropyl
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89306228A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0358305A1 (en
Inventor
Ian C/O Beecham Pharmaceuticals Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to AT89306228T priority Critical patent/ATE93517T1/de
Publication of EP0358305A1 publication Critical patent/EP0358305A1/en
Application granted granted Critical
Publication of EP0358305B1 publication Critical patent/EP0358305B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel thiophenol derivatives, processes for their preparation and their use in medicine.
  • the present invention relates to their use as collagenase inhibitors for treating arthritic and other diseases.
  • the range of therapeutic applications of the collagenase inhibitors described hereinafter reflects the fundamental role of collagen within the connective tissue matrix throughout the body, and extends to many diseases not primarily due to collagen destruction but involving tissue remodelling, as these will also be susceptible to clinical intervention with collagenase inhibitors.
  • inhibition of collagenases released from synovial and skin fibroblasts, chondrocytes, peripheral mononuclear cells, keratinocytes and gingival tissue, as well as inhibition of collagenase stored in polymorphonuclear leucocytes (PMNLs) should be of therapeutic value, and the present compounds are envisaged as having application against these and related mammalian collagenases, and related neutral metalloproteases.
  • collagenase inhibitors will provide useful treatments for arthritic diseases such as rheumatoid arthritis and osteoarthritis, soft tissue rheumatism, polychondritis and tendonitis; for bone resorption diseases such as osteoporosis, Paget's disease, hyperparathyroidism and cholesteatoma; for the recessive classes of dystrophic epidermolysis bullosa; for periodontal disease and related consequences of gingival collagenase production or of PMNL collagenase production following cellular infiltration to inflamed gingiva; for corneal ulceration e.g.
  • a collagenase inhibitor may also be of use in some post-operative conditions such as colonic anastomosis in which collagenase levels are raised.
  • collagenase inhibitors As a particular example of the therapeutic value of collagenase inhibitors, chronic arthritic diseases lead to extensive loss of the collagen and proteoglycan components within the cartilage and bone of the affected joints.
  • Neutral metalloproteases especially collagenases, proteoglycanases (stromelysins) and gelatinases, are currently thought to be the major enzymes involved.
  • US Patent No. 4,595,700 discloses compounds of the formula (A): in which: R a represents lower alkyl, phenyl or phenyl lower alkyl; R b and R d represent lower alkyl; and R c represents lower alkyl, benzyloxyalkyl, alkoxybenzyl or benzyloxybenzyl wherein the oxyalkyl or alkoxy moiety contains 1 to 6 carbon atoms and a, b and c represent chiral centres with optional R or S stereochemistry.
  • R a represents lower alkyl, phenyl or phenyl lower alkyl
  • R b and R d represent lower alkyl
  • R c represents lower alkyl, benzyloxyalkyl, alkoxybenzyl or benzyloxybenzyl wherein the oxyalkyl or alkoxy moiety contains 1 to 6 carbon atoms and a, b and c represent chiral centres with optional R or S stereochemistry.
  • a compound of general formula (I), or a salt, solvate or hydrate thereof in which: R1 and R2 are independently hydrogen; alkyl; alkoxy; halogen; or CF3; R3 is hydrogen; acyl, such as where Z is aryl optionally substituted by OH, C1 ⁇ 6alkyl, C1 ⁇ 6alkoxy or halogen; or a group R-S- where R is C1 ⁇ 6alkyl or an organic residue such that the compound of formula (I) is a dimer about the disulphide bond; R4 is C3 ⁇ 6 alkyl; R5 is hydrogen; alkyl; -CH2-R10 where R10 is phenyl or heteroaryl each of which may be optionally substituted by OH, C1 ⁇ 6alkyl, C1 ⁇ 6alkoxy or halogen or a group where R11 is hydrogen; alkyl; or -CH2-Ph where Ph is phenyl optionally substituted by OH, C1
  • each alkyl or alkoxy group is a C1 ⁇ 8 group, more preferably C1 ⁇ 6, and may be a straight chain or branched.
  • Optional substituents for aryl and heteroaryl groups may be selected from OH, C1 ⁇ 6 alkyl, C1 ⁇ 6 alkoxy and halogen.
  • R1 and R2 include hydrogen, C1 ⁇ 4 alkyl especially methyl, C1 ⁇ 4 alkoxy especially methoxy, halogen especially chlorine, and CF3.
  • both R1 and R2 are hydrogen or one of R1 and R2 is hydrogen and the other is C1 ⁇ 4 alkyl especially methyl, C1 ⁇ 4 alkoxy especially methoxy, halogen especially chorine, or CF3.
  • R3 is Z is preferably an optionally substituted phenyl group.
  • R3 is preferably hydrogen, benzoyl, or a group R-S- where R is a C1 ⁇ 6 alkyl group or such that the compound of formula (I) is a dimer about the disulphide bond.
  • An R3 hydrogen is especially preferred.
  • R4 is preferably a C4 alkyl group, such as n -butyl, iso -butyl or sec -butyl, especially iso -butyl.
  • R10 When R5 is -CH2-R10 and R10 is heteroaryl, values for R10 include 5- or 6- membered monocyclic and 9- or 10-membered bicyclic heteroaryl of which 9- or 10-membered bicyclic heteroaryl is preferred.
  • 5- or 6- membered monocyclic and 9- or 10-membered bicyclic heteroaryl preferably contain one or two heteroatoms selected from nitrogen, oxygen and sulphur.
  • R10 is 9- or 10- membered bicyclic heteroaryl the two rings are preferably fused with one 5- or 6- membered ring containing a single heteroatom, for example indolyl.
  • R5 is preferably iso -butyl; benzyl; or C1 ⁇ 6 alkoxybenzyl, such as 4-methoxybenzyl; 1-(benzyloxy)ethyl; or 9- or 10- membered fused bicyclic heteroarylmethyl such as 3-indolylmethyl.
  • R6 include hydrogen; alkyl, such as methyl or ethyl, preferably methyl; and 1-(methoxycarbonyl)ethyl.
  • n is preferably zero.
  • the compounds of formula (I) may form salts with bases e.g. sodium hydroxide.
  • bases e.g. sodium hydroxide.
  • the compounds of formula (I) may form acid addition salts e.g. with hydrochloric acid. Such compounds form part of the present invention.
  • the compounds of formula (I) have at least one asymmetric centre and therefore exist in more than one stereoisomeric form.
  • the invention extends to all such forms and to mixtures thereof, including racemates, and diastereoisomeric mixtures.
  • Preferred isomers are those having the S configuration at the chiral centre marked with an asterisk in formula (I), when R5 is other than hydrogen.
  • the compounds of formula I or their salts, solvates or hydrates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • a substantially pure form will generally contain at least 50% by weight, preferably 75%, more preferably 90% and still more preferably 95% or 99% or more of the compound of formula I or its salt or solvate.
  • One preferred pharmaceutically acceptable form is the crystalline form.
  • the present invention provides the compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof for use as active therapeutic agents, particularly as agents for treatment of musculo-skeletal disorders resulting from collagenolytic activity, particularly arthritic diseases, and tissue remodelling, and also for the systemic chemotherapy of cancer.
  • the present invention also provides a process for the preparation of a compound of formula (I) in which R3 is hydrogen, which comprises cleaving a group P from a compound of formula (II): wherein P is P1 which is a conventional sulphur protecting group or P2 which is a group R′-S- where R′ is any organic residue such that the group R′-S-provides a cleavable disulphide bond, R11 and R21 are R1 and R2 respectively as defined for formula (I) or groups convertible thereto, and R4, R5, R6, X and Y are as defined for formula (I), and thereafter, as required, converting R11 to R1 and R21 to R2.
  • a protecting group P1 is an optionally substituted benzyl group, such as benzyl or alkoxybenzyl e.g. 4-methoxybenzyl, an aliphatic or aryl acyl group such as acetyl or benzoyl, or a tertiary butyl group.
  • benzyl or alkoxybenzyl e.g. 4-methoxybenzyl
  • an aliphatic or aryl acyl group such as acetyl or benzoyl
  • a tertiary butyl group a protecting group P1 is an optionally substituted benzyl group, such as benzyl or alkoxybenzyl e.g. 4-methoxybenzyl, an aliphatic or aryl acyl group such as acetyl or benzoyl, or a tertiary butyl group.
  • P1 is a tertiary butyl group or a substituted benzyl sulphur protecting group, such as 4-methoxy benzyl
  • P1 may be removed by treatment with mercuric acetate in trifluoroacetic acid containing anisole followed by reaction with hydrogen sulphide in dimethyl formamide, in a procedure analogous to that described in Chem. Pharm. Bull [1978], 26 , 1576.
  • P1 When P1 is an acyl group it may be removed by treatment with a base, for example aqueous ammonia or dilute aqueous sodium hydroxide, or by treatment with an acid, for example methanolic hydrochloric acid.
  • a base for example aqueous ammonia or dilute aqueous sodium hydroxide
  • an acid for example methanolic hydrochloric acid.
  • the protecting group may be cleaved using sodium in liquid ammonia.
  • the disulphide bond may be cleaved by treatment with zinc and hydrochloric acid, sodium borohydride, an excess of a thiol such as ⁇ -mercaptoethanol or dithiothreitol, or by passing hydrogen sulphide through a solution of the disulphide.
  • variables R11 and R21 to R1 and R2 respectively may be carried out using procedures commonly used in the organic chemistry of aromatic compounds. Unless they are unstable under the reaction conditions used to prepare the compounds of the invention, variables R11 and R21 in compounds of formula (II) are generally identical to variables R1 and R2 respectively in compounds of formula (I).
  • the intermediate compounds of formula (II) may be prepared by treating a compound of formula (III): in which R11, R21, R4, X, Y and P are as defined in formula (II), with a compound of formula (IV): in which R5 and R6 are as defined in formula (I).
  • the reaction is preferably carried out in the presence of a coupling agent such as N,N′-dicyclohexylcarbodiimide or N-ethyl-N′-dimethylaminopropylcarbodiimide.
  • a coupling agent such as N,N′-dicyclohexylcarbodiimide or N-ethyl-N′-dimethylaminopropylcarbodiimide.
  • the intermediate compounds of formula (III) may be prepared by hydrolysis and subsequent decarboxylation of malonic ester derivatives of formula (V): in which R11, R21, R4, X, Y and P are as defined in formula (II) and each R7 is a hydrolysable ester group.
  • the hydrolysis may be carried out under basic conditions, for example by heating in aqueous sodium or potassium hydroxide solution.
  • Decarboxylation of the resulting malonic acid derivative may be carried out by heating in a high boiling solvent, for example xylene.
  • the intermediate compounds of formula (V) may be prepared by reaction of a compound of formula (VI): in which R11, R21, X, Y and P are as defined in formula (II) and L is a leaving group, with a compound of formula (VII): in which R4 and R7 are as defined in formula (V).
  • the reaction is preferably carried out by a standard malonic ester synthesis in which the ester groups R7 in the compound of formula (VII) are ethyl ester groups.
  • Suitable values for the leaving group L in compounds of formula (VI) include halogen such as chlorine and bromine, and sulphonyloxy derivatives such as methanesulphonyloxy and p-toluenesulphonyloxy.
  • the leaving group L in compounds of formula (VI) may be introduced using standard procedures.
  • a halogen leaving group L may be introduced by reaction of a compound of formula (VI) in which L is an amino function with, for example, ethyl chloroformate
  • a sulphonyloxy leaving group may be introduced by reaction of a compound of formula (VI) in which L is hydroxy with, for example, a sulphonyl halide such as methanesulphonyl chloride or p-toluenesulphonyl chloride, suitably at reduced temperature and in the presence of a chloride-ion scavenger.
  • the sulphonyloxy group so introduced may be readily displaced by chloride ions to provide a chlorine leaving group.
  • the intermediate compounds of formula (III) may be prepared directly by reaction of compounds of formula (VI) with the dianion of compounds of formula (VII) in which one R7 is hydrogen and the other R7 is a carboxyl group.
  • This procedure necessitates the use of a sulphur protecting group P1 in compounds of formula (VI) which has no acidic protons, for example a tertiary butyl group.
  • the compounds of formula (IV) are either known amino acid derivatives or can be made from these derivatives by known methods.
  • Malonic ester compounds of formula (VII) are generally known compounds or can be prepared using standard procedures from known compounds.
  • compounds of formula (VI) in which P is P1 where P1 is an acyl group may be prepared by acylation of the corresponding phenylmercaptan.
  • salts of the compounds of formula (I) may be formed conventionally by reaction with the appropriate acid or base.
  • Solvates may be formed by crystallization from the appropriate solvent.
  • the compounds of formula (I) exist in more than one diastereoisomeric form.
  • the processes of the invention produce mixtures thereof, the individual isomers may be separated one from another by chromatography, e.g. by HPLC or by conventional silica gel column chromatography.
  • separate diastereoisomeric compounds of formula (I) can be obtained by using stereoisomerically pure starting materials or by separating desired isomers of intermediates at any stage in the overall synthetic process, and converting these intermediates to compounds of formula (I).
  • the present invention further provides a pharmaceutical composition, which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier.
  • a composition of this invention is useful in the treatment of rheumatism and arthritis and in the treatment of other collagenolytic conditions.
  • a composition of the invention which may be prepared by admixture, may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • these conventional excipients may be employed in conventional manner, for example as in the preparation of compositions of related peptide enzyme inhibitors, such as the ACE inhibitor captopril.
  • a composition of the invention may be adapted for oral, topical, percutaneous, rectal or parenteral - intravenous, intramuscular, sub-cutaneous, intradermal or intra-articular administration, but oral administration is preferred.
  • a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment or prophylaxis of any of the disorders mentioned above.
  • the suitable dosage range for the compounds of the invention may vary from compound to compound and may depend on the condition to be treated. It will also depend, inter alia , upon the relation of potency to absorbability and the mode of administration chosen.
  • the compound or composition of the invention may be formulated for administration by any route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • compositions may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinylpyrrolidone,
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • a hard gelatin capsule containing the required amount of a compound of the invention in the form of a powder or granulate in intimate mixture with a lubricant, such as magnesium stearate, a filler, such as microcrystalline cellulose, and a disintegrant, such as sodium starch glycollate.
  • a lubricant such as magnesium stearate
  • a filler such as microcrystalline cellulose
  • a disintegrant such as sodium starch glycollate
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colour
  • compositions may be formulated, for example for rectal administration as a suppository or for parenteral administration in an injectable form.
  • the compounds of the invention may be presented in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g.
  • sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids which may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • bacteriostatic agents anti-oxidants or other preservatives
  • buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in sterile unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the preparations may also be presented as an ointment, cream, lotion, gel, spray, aerosol, wash or skin paint or patch.
  • a unit dose for inflammatory diseases will generally contain from 10 to 1000 mg and preferably will contain from 10 to 500 mg, in particular 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg.
  • the composition may be administered once or more times a day, for example 2, 3 or 4 times daily, so that the total daily dose for a 70 kg adult will normally be in the range 10 to 3000 mg.
  • the unit dose will contain from 2 to 200 mg of a compound of the invention and be administered in multiples, if desired, to give the desired daily dose.
  • the present invention additionally provides a method of treating a collagenolytic condition such as rheumatism and/or arthritic conditions, or cancer, or other diseases in which enzyme-mediated breakdown of connective tissue components plays a role in mammals, such as humans, which comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof, to the mammal.
  • a collagenolytic condition such as rheumatism and/or arthritic conditions, or cancer, or other diseases in which enzyme-mediated breakdown of connective tissue components plays a role in mammals, such as humans, which comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof, to the mammal.
  • the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the manufacture of a medicament for use as an active therapeutic substance, particularly in the treatment of collagenolytic conditions, such as rheumatism, cancer, bone disorders, skin diseases, periodontal disease or corneal ulceration, in mammals.
  • collagenolytic conditions such as rheumatism, cancer, bone disorders, skin diseases, periodontal disease or corneal ulceration
  • N,N′-Dicyclohexylcarbodiimide (0.83 g, 4.0 mmol) was added to an ice-cooled solution of 2-benzylthio- ⁇ -(2-methylpropyl)phenylpropanoic acid (1.20 g, 3.65 mmol) in dry dichloromethane (30 ml). After 15 min, O-methyl-L-tyrosine N-methylamide (0.76 g, 3.65 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was cooled in ice for 60 min, filtered, and the filtrate was washed successively with water, 1 M hydrochloric acid water, saturated sodium hydrogen carbonate and brine.
  • N-Ethyl-N′-dimethylaminopropylcarbodiimide (420 mg, 2.2 mmol) was added to an ice-cooled solution of 2-benzylthio-3-methoxy- ⁇ -(2-methylpropyl)phenylpropanoic acid (750 mg, 2.1 mmol) in dichloromethane (30 ml). After 10 min, O-methyl-L-tyrosine N-methylamide (435 mg, 2.1 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was diluted with dichloromethane and was washed successively with water, saturated sodium hydrogen carbonate, water, 1 M hydrochloric acid and brine, then was dried (MgSO4) and evaporated in vacuo .
  • N-Ethyl-N′-dimethylaminopropylcarbodiimide (230 mg, 1.2 mmol) was added to an ice-cooled solution of 4-chloro-2-(4-methoxybenzylthio)- ⁇ -(2-methylpropyl)phenylpropanoic acid (D22) (392 mg, 1 mmol) and 1-hydroxybenzotriazole (162 mg, 1.2 mmol) in dichloromethane (15 ml). After 15 min, O-methyl-L-tyrosine N-methylamide (218 mg, 1 mmol) was added.
  • the title compound was prepared as a 1:1 mixture of diastereoisomers from the compound of Description 2 using procedures described in Description 30 and Example 1, mp 166-171 o C (after trituration with diethyl ether followed by pentane).
  • the title compound was prepared as a 1:1 mixture of diastereoisomers from 3-chloro-2-(4-methoxybenzylthio)-N-[2-(4-methoxyphenyl)-1-(S)-(methylaminocarbonyl)ethyl]- ⁇ -(2-methylpropyl)phenylpropanamide in a similar manner to that described in Example 4, mp 68-74 o C (after trituration with hexane).
  • the title compound was prepared as a 1:1 mixture of diasteresisomers from 3-chloro-2-(4-methoxybenzylthio)- ⁇ -(2-methylpropyl)-N-(2-oxo-3-azacylotridecyl)phenylpropanamide in a similar manner to that described in Example 4, mp 143-148 o C (after trituration with hexane).
  • the title compound was prepared from the compound of Example 1B by oxidative coupling in methanol in the presence of iodine, mp 193-197 o C.
  • the title compound is prepared from 2-(tert-butylthio)-N-[2-(4-methoxyphenyl)-1-(S)-(methylaminocarbonyl)ethyl]- ⁇ -(2-methylpropyl)phenylbutanamide in a similar manner to that described in Example 4.
  • the test is performed essentially as in Cawston and Barrett, Anal. Biochem. 99 , 340-345 (1979).
  • Compounds for testing are dissolved in methanol and added to collagenase (purified from cultures of rabbit bone or from culture supernatants from the human lung fibroblast cell line, WI-38) in buffer.
  • collagenase purified from cultures of rabbit bone or from culture supernatants from the human lung fibroblast cell line, WI-38
  • ⁇ -mercaptoethanol may be incorporated in the methanol solvent and/or the diluent buffers. The minimal direct effect of ⁇ -mercaptoethanol on the degradation of collagen by human or rabbit collagenase is controlled for.
  • the assay tubes are cooled to 4 o C and 14C-acetylated rat skin Type II collagen is added.
  • the assay tubes are incubated at 37 o C overnight.
  • the 14C-collagen forms insoluble fibrils which are the substrate for the enzyme.
  • the assay tubes are spun at 12000 rpm for 15 min. Undigested 14C-collagen is pelleted, while digested 14C-collagen is found as soluble peptides in the supernatant. A sample of the supernatant is taken for liquid scintillation counting.
  • IC50 50% inhibitory concentration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP89306228A 1988-06-22 1989-06-20 Mercapto-phenylalcanoylamino acid amides, their preparation and their use as collagenase inhibitors Expired - Lifetime EP0358305B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89306228T ATE93517T1 (de) 1988-06-22 1989-06-20 Mercapto-phenylalkanoylaminosaeure-amide, deren herstellung und deren verwendung als collagenase- inhibitoren.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8814813 1988-06-14
GB888814813A GB8814813D0 (en) 1988-06-22 1988-06-22 Novel compounds

Publications (2)

Publication Number Publication Date
EP0358305A1 EP0358305A1 (en) 1990-03-14
EP0358305B1 true EP0358305B1 (en) 1993-08-25

Family

ID=10639132

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89306228A Expired - Lifetime EP0358305B1 (en) 1988-06-22 1989-06-20 Mercapto-phenylalcanoylamino acid amides, their preparation and their use as collagenase inhibitors

Country Status (15)

Country Link
US (1) US5124322A (enrdf_load_stackoverflow)
EP (1) EP0358305B1 (enrdf_load_stackoverflow)
JP (1) JPH0253765A (enrdf_load_stackoverflow)
KR (1) KR910000614A (enrdf_load_stackoverflow)
AT (1) ATE93517T1 (enrdf_load_stackoverflow)
AU (1) AU615554B2 (enrdf_load_stackoverflow)
DE (1) DE68908643T2 (enrdf_load_stackoverflow)
DK (1) DK304289A (enrdf_load_stackoverflow)
ES (1) ES2058531T3 (enrdf_load_stackoverflow)
GB (1) GB8814813D0 (enrdf_load_stackoverflow)
IE (1) IE891998L (enrdf_load_stackoverflow)
NZ (1) NZ229630A (enrdf_load_stackoverflow)
PT (1) PT90912B (enrdf_load_stackoverflow)
TW (1) TW197421B (enrdf_load_stackoverflow)
ZA (1) ZA894671B (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
DE69626544T2 (de) * 1995-12-22 2004-01-15 Lilly Co Eli Arzneistoffe
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
US7195759B2 (en) * 2001-06-06 2007-03-27 The University Of Manitoba Therapeutic uses of glandular kallikrein
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
SI2854841T1 (sl) 2012-06-04 2017-06-30 Diamedica Inc. Glikozilacijske izooblike humanega tkivnega kalikreina-1
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. TISSUE KALLICREIN DOSAGE FORMS 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623729A (en) * 1982-07-22 1986-11-18 E. R. Squibb & Sons, Inc. Acylalkylaminocarbonyl substituted amino and imino acid compounds
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
AU599736B2 (en) * 1986-12-24 1990-07-26 Beecham Group Plc Thiol-carboxylic acid derivatives
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.

Also Published As

Publication number Publication date
DE68908643D1 (de) 1993-09-30
PT90912B (pt) 1994-12-30
ES2058531T3 (es) 1994-11-01
US5124322A (en) 1992-06-23
GB8814813D0 (en) 1988-07-27
EP0358305A1 (en) 1990-03-14
ZA894671B (en) 1990-07-25
AU615554B2 (en) 1991-10-03
TW197421B (enrdf_load_stackoverflow) 1993-01-01
AU3667589A (en) 1990-01-04
JPH0253765A (ja) 1990-02-22
DE68908643T2 (de) 1994-03-17
PT90912A (pt) 1989-12-29
DK304289A (da) 1989-12-23
KR910000614A (ko) 1991-01-29
NZ229630A (en) 1991-12-23
IE891998L (en) 1989-12-22
DK304289D0 (da) 1989-06-20
ATE93517T1 (de) 1993-09-15

Similar Documents

Publication Publication Date Title
EP0358305B1 (en) Mercapto-phenylalcanoylamino acid amides, their preparation and their use as collagenase inhibitors
US4154840A (en) Antihypertensive pipecolic acid derivatives
EP0320118B1 (en) Peptides with collagenase inhibiting activity
US5319082A (en) N-acylamino acid derivatives
EP1200457B1 (en) Cysteine protease inhibitors
EP0273689B1 (en) Derivatives of n-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors
US5530128A (en) N-sulphonylamino derivatives of dipetide compounds as metalloproteinase inhibitors
DE69607615T2 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
HU211983A9 (en) Hydroxamic acid based collagenase inhibitors
EP0859784B1 (en) Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
EA005563B1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EP0322184B1 (en) N-(2-alkyl-3-mercapto-1,5-di-oxoalkyl)glycinamide derivatives and their use as collagenase inhibitors
AU8660491A (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
AU713477B2 (en) Peptidyl compounds having MMP and TNF inhibitory activity
US4252943A (en) Carbamate derivatives of mercaptoacyl hydroxy prolines
GB2088875A (en) Carbamate Derivatives of Hydroxy Prolines
WO1992017444A1 (en) Thiol-carboxylic acid derivatives as collagenase inhibitors
MXPA98008924A (en) Azetidinone derivatives for deeterosclero treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUGHES, IAN C/O BEECHAM PHARMACEUTICALS

17P Request for examination filed

Effective date: 19900423

17Q First examination report despatched

Effective date: 19911216

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 93517

Country of ref document: AT

Date of ref document: 19930915

Kind code of ref document: T

REF Corresponds to:

Ref document number: 68908643

Country of ref document: DE

Date of ref document: 19930930

ITF It: translation for a ep patent filed
ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3009872

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19940421

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19940430

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19940511

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19940519

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19940526

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19940613

Year of fee payment: 6

Ref country code: ES

Payment date: 19940613

Year of fee payment: 6

EPTA Lu: last paid annual fee
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19940630

Year of fee payment: 6

Ref country code: DE

Payment date: 19940630

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19940707

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19940715

Year of fee payment: 6

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2058531

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 89306228.1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19950620

Ref country code: GB

Effective date: 19950620

Ref country code: AT

Effective date: 19950620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19950621

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19950621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19950630

Ref country code: CH

Effective date: 19950630

Ref country code: BE

Effective date: 19950630

BERE Be: lapsed

Owner name: BEECHAM GROUP P.L.C.

Effective date: 19950630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19951231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19960101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19950620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19960229

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3009872

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19960101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19960301

EUG Se: european patent has lapsed

Ref document number: 89306228.1

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19990503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050620